10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



Anti-ALCAM / CD166 Reference Antibody (praluzatamab)

Recombinant Antibody Catalog # APR10071

Product Information

Application FC, Kinetics, Animal Model

Primary Accession

Reactivity

Clonality

Isotype

Calculated MW

Q13740

Human

Monoclonal

IgG1

65102

Additional Information

Target/Specificity ALCAM / CD166

Endotoxin

Conjugation Unconjugated

Expression system CHO Cell

Format Purified monoclonal antibody supplied in PBS, pH6.0, without

preservative. This antibody is purified through a protein A column.

Protein Information

Name ALCAM

Synonyms MEMD {ECO:0000303 | PubMed:9502422}

Function Cell adhesion molecule that mediates both heterotypic cell- cell contacts via

its interaction with CD6, as well as homotypic cell- cell contacts

(PubMed: 15048703, PubMed: 15496415, PubMed: 16352806,

PubMed:23169771, PubMed:24945728, PubMed:7760007). Promotes T-cell activation and proliferation via its interactions with CD6 (PubMed:15048703, PubMed:16352806, PubMed:24945728). Contributes to the formation and maturation of the immunological synapse via its interactions with CD6 (PubMed:15294938, PubMed:16352806). Mediates homotypic interactions with cells that express ALCAM (PubMed:15496415, PubMed:16352806). Acts as a ligand for the LILRB4 receptor, enhancing LILRB4-mediated inhibition of T cell proliferation (PubMed:29263213). Required for normal hematopoietic stem cell engraftment in the bone marrow (PubMed:24740813). Mediates attachment of dendritic cells onto endothelial cells via homotypic interaction (PubMed:23169771). Inhibits endothelial cell migration and promotes endothelial tube formation via homotypic interactions (PubMed:15496415, PubMed:23169771). Required for normal organization of the lymph vessel network. Required for normal hematopoietic stem cell engraftment in the

bone marrow. Plays a role in hematopoiesis; required for normal numbers of hematopoietic stem cells in bone marrow. Promotes in vitro osteoblast proliferation and differentiation (By similarity). Promotes neurite extension, axon growth and axon guidance; axons grow preferentially on surfaces that contain ALCAM. Mediates outgrowth and pathfinding for retinal ganglion cell axons (By similarity).


Cellular Location

Cell membrane; Single-pass type I membrane protein. Cell projection, axon {ECO:0000250 | UniProtKB:Q61490}. Cell projection, dendrite {ECO:0000250 | UniProtKB:Q61490}. Note=Detected at the immunological synapse, i.e, at the contact zone between antigen-presenting dendritic cells and T-cells (PubMed:15294938, PubMed:16352806). Colocalizes with CD6 and the TCR/CD3 complex at the immunological synapse (PubMed:15294938).


Tissue Location

Detected on hematopoietic stem cells derived from umbilical cord blood (PubMed:24740813). Detected on lymph vessel endothelial cells, skin and tonsil (PubMed:23169771). Detected on peripheral blood monocytes (PubMed:15048703). Detected on monocyte- derived dendritic cells (at protein level) (PubMed:16352806). Detected at low levels in spleen, placenta, liver (PubMed:9502422). Expressed by activated T-cells, B-cells, monocytes and thymic epithelial cells (PubMed:7760007). Isoform 1 and isoform 3 are detected in vein and artery endothelial cells, astrocytes, keratinocytes and artery smooth muscle cells (PubMed:15496415). Expressed by neurons in the brain Restricted expression in tumor cell lines. Detected in highly metastasizing melanoma cell lines (PubMed:9502422)


Images



Anti-ALCAM / CD166 Reference Antibody (praluzatamab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-ALCAM / CD166 Reference Antibody (praluzatamab)is more than 100% ,determined by SEC-HPLC.



Immobilized human ALCAM His at 2 µg/mL can bind Anti-ALCAM / CD166 Reference Antibody (praluzatamab),EC50=0.00698 µg/mL

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.